| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 12.5% |
| ABBOTT LABS | 8 | Q3 2017 | 9.4% |
| REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 7.1% |
| POTASH CORP SASK INC | 8 | Q3 2017 | 2.2% |
| GW PHARMACEUTICALS PLC | 8 | Q3 2017 | 4.1% |
| GW PHARMACEUTICALS PLC | 8 | Q3 2017 | 2.2% |
| INOTEK PHARMACEUTICALS CORP | 8 | Q3 2017 | 1.3% |
| SAREPTA THERAPEUTICS INC | 8 | Q3 2017 | 2.9% |
| REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 2.9% |
| VALEANT PHARMACEUTICALS INTL | 8 | Q3 2017 | 2.0% |
View FT Options LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-10 |
| 13F-HR | 2016-11-10 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-09 |
| 13F-HR | 2016-02-05 |
View FT Options LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.